RLM - Realm Therapeutics plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 511.89M
Enterprise Value 3-7.23M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)46.93
Price/Book (mrq)0.56
Enterprise Value/Revenue 3-28.55
Enterprise Value/EBITDA 60.55

Trading Information

Stock Price History

Beta (3Y Monthly) N/A
52-Week Change 3∞%
S&P500 52-Week Change 3-0.33%
52 Week High 313.0000
52 Week Low 31.3500
50-Day Moving Average 32.7200
200-Day Moving Average 33.1150

Share Statistics

Avg Vol (3 month) 326.28k
Avg Vol (10 day) 394k
Shares Outstanding 54.66M
Float 1.44M
% Held by Insiders 131.10%
% Held by Institutions 146.35%
Shares Short (Jul 15, 2019) 49.39k
Short Ratio (Jul 15, 2019) 40.51
Short % of Float (Jul 15, 2019) 4N/A
Short % of Shares Outstanding (Jul 15, 2019) 40.21%
Shares Short (prior month Jun 14, 2019) 411.25k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Dec 31, 2018

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-5,219.74%

Management Effectiveness

Return on Assets (ttm)-29.03%
Return on Equity (ttm)-50.90%

Income Statement

Revenue (ttm)253.34k
Revenue Per Share (ttm)0.05
Quarterly Revenue Growth (yoy)-49.50%
Gross Profit (ttm)253.34k
EBITDA -13.16M
Net Income Avi to Common (ttm)-13.63M
Diluted EPS (ttm)-2.9230
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)18.89M
Total Cash Per Share (mrq)4.05
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)41.37
Book Value Per Share (mrq)4.58

Cash Flow Statement

Operating Cash Flow (ttm)-14.97M
Levered Free Cash Flow (ttm)-11.12M